Suketi Rathore
Investment Advisor, Norwest India·Norwest
Bio
Professional summary
Suketi Rathore is an investment advisor with Norwest India focused on early-stage and growth equity investments in Indian companies across sectors. Before joining Norwest, she was an investment banking analyst at Avendus Capital, where she advised enterprise technology and services companies on M&A and fundraising transactions. She holds a bachelor of commerce degree from Shri Ram College of Commerce.
Background
Career, education, and skills
Career history
- NorwestInvestment Advisor, Norwest India
- Avendus CapitalInvestment Banking Analyst
Education
- Shri Ram College of CommerceBachelor of Commerce
Other partners at Norwest
12 more profiles
Abishek Balakrishnan
Investor
Norwest
Norwest growth equity investor focused on healthcare services, IT, devices, and digital health.
Aidan Greenstein
Investor
Norwest
Norwest growth equity investor covering technology, business services, media, and consumer.
Amalia Mackenzie
Investor
Norwest
Norwest venture investor focused on consumer and enterprise software.
Amy Brand
Investor
Norwest
Norwest growth equity investor and former Barclays financial sponsors banker.
Andrew Ellis
Investor
Norwest
Norwest growth equity investor focused on software and tech-enabled services.
Angela Johnson
Vice President
Norwest
Norwest growth equity VP focused on technology, business services, media, and consumer.
Anjini K.
Investor
Norwest
Norwest healthtech venture investor with prior Oscar Health and McKinsey experience.
Ankit Prasad
Norwest India
Norwest
Norwest India investor focused on venture and growth equity across Indian companies.
Apurva Oak
Investor
Norwest
Healthcare growth investor focused on software and services at Norwest.
Aria Shah
Investment Professional
Norwest
Growth investment professional with healthcare and venture capital experience.
Assaf Harel
Partner
Norwest
Norwest Partner focused on Israeli-related multi-stage technology investments.
Brian Matesic, MD
Principal
Norwest
Life sciences investor backing early- to mid-stage biotech and medtech companies.